<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620100</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976A_2504</org_study_id>
    <nct_id>NCT00620100</nct_id>
  </id_info>
  <brief_title>To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent</brief_title>
  <official_title>A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere®) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed &gt; or = 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin&#xD;
      or doxorubicine) followed by 4 cycles of docetaxel single agent. To determine the Time to&#xD;
      Tumor Progression (TTP), the Response Duration, the Overall Survival. To confirm the safety&#xD;
      profile&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the study was early terminated due to lack of recruitment.&#xD;
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the objective response rate according to RECIST guidelines after treatment with Taxoterer and anthracycline followed by Taxoterer single agent in the first line treatment of Her2 negative locally advanced or metastatic breast cancer</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Time to Tumor Progression (TTP).</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the response duration.</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall survival.</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To confirm the safety profile.</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patient with histologically or cytologically documented breast adenocarcinoma&#xD;
&#xD;
          2. First local or metastatic relapse&#xD;
&#xD;
          3. Patients must have received a prior neoadjuvant or adjuvant Taxotere®-based&#xD;
             chemotherapy regimen, provided this chemotherapy was completed &gt; than or = to 12&#xD;
             months prior to enrollment date&#xD;
&#xD;
          4. Prior hormone or immune therapy is allowed. Antitumoral adjuvant hormone therapy may&#xD;
             be continued during the study period, provided it was started &gt; 12 months prior to&#xD;
             study enrollment&#xD;
&#xD;
          5. Her2/neu negative tumor demonstrated by immunohistochemistry (IHC 0 or 1+) or by&#xD;
             fluorescence in situ hybridation (FISH -). A patient with tumor assessed as 2+ by IHC&#xD;
             can be enrolled if the tumor is negative by FISH.&#xD;
&#xD;
          6. ECOG performance status of 0 to 2&#xD;
&#xD;
          7. Normal cardiac function confirmed by LVEF or shortening fraction (MUGA scan or&#xD;
             echocardiography, respectively, within normal limits for the institution) assessed&#xD;
             within 3 months prior to study entry. An ECG must be obtained within 4 weeks prior&#xD;
             study entry and must demonstrate no clinically significant abnormality.&#xD;
&#xD;
          8. Patients are required to have at least one measurable lesion according to RECIST&#xD;
             guidelines&#xD;
&#xD;
          9. Adequate organ function defined by:&#xD;
&#xD;
               1. Hematology: Neutrophils &gt; than or = to 2.0 109/L, Platelets &gt; than or = to 100&#xD;
                  109/L, Hemoglobin &gt; than or = to 10 g/dL&#xD;
&#xD;
               2. Hepatic function: Total bilirubin within normal limits, AST (SGOT) and ALT (SGPT)&#xD;
                  &lt; than or = to 1.5 UNL, alkaline phosphatase &lt; than or = to 2.5 UNL (unless&#xD;
                  accompanied by extensive bone metastases)&#xD;
&#xD;
         10. Negative pregnancy test (urine or serum) within 7 days prior to registration for all&#xD;
             women of childbearing potential&#xD;
&#xD;
         11. Written informed consent prior to beginning specific protocol procedures must be&#xD;
             obtained and documented according to the local regulatory requirements&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior therapy for advanced or recurrent disease&#xD;
&#xD;
          2. Previous cumulative exposure to epirubicin &gt; 600 mg/m² or to doxorubicin &gt; 300 mg/m²&#xD;
&#xD;
          3. Previous radiation therapy having involved more than 25% of bone marrow; incomplete&#xD;
             recovery from toxicity of radiation therapy&#xD;
&#xD;
          4. Symptomatic brain metastases and clinically diagnosed leptomeningeal metastases&#xD;
&#xD;
          5. Isolated unmeasurable bone lesions, serous pleural effusion or pulmonary lymphangiitis&#xD;
             (i.e., unmeasurable disease according to the RECIST guidelines)&#xD;
&#xD;
          6. Pre-existing motor or sensory neurologic toxicity of a severity &gt; than or = to grade 2&#xD;
             according to NCI-CTC AE criteria version 3.0&#xD;
&#xD;
          7. Pregnant or lactating women or women of childbearing potential not using adequate&#xD;
             contraception&#xD;
&#xD;
          8. Other serious illness or medical conditions, including:&#xD;
&#xD;
               1. Congestive heart failure or unstable angina pectoris, previous history of&#xD;
                  myocardial infarction within 1 year from study entry, uncontrolled hypertension&#xD;
                  or high-risk uncontrolled arrhythmias&#xD;
&#xD;
               2. History of significant neurologic or psychiatric disorders including psychotic&#xD;
                  disorders, dementia or seizures that would hamper understanding and giving&#xD;
                  informed consent.&#xD;
&#xD;
               3. Active uncontrolled infection&#xD;
&#xD;
               4. Active peptic ulcer, uncontrolled diabetes mellitus&#xD;
&#xD;
          9. Past or current history of neoplasm other than breast carcinoma, except:&#xD;
&#xD;
               1. Curatively treated non-melanoma skin cancer.&#xD;
&#xD;
               2. in situ carcinoma of the cervix.&#xD;
&#xD;
               3. Other cancer curatively treated and with no evidence of disease for at least 10&#xD;
                  years&#xD;
&#xD;
         10. Chronic treatment with corticosteroids unless initiated &gt; 6 months prior to study&#xD;
             entry and at low dose (&lt; than or = to 20 mg methylprednisolone per day or equivalent)&#xD;
&#xD;
         11. Definite contraindications for the use of corticosteroids&#xD;
&#xD;
         12. Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical study protocol (see Section 6.2)&#xD;
&#xD;
         13. Concurrent treatment with other investigational drugs. Active treatment as part of&#xD;
             another clinical therapeutic trial within 30 days prior to study entry&#xD;
&#xD;
         14. Concurrent treatment with any other anti-cancer therapy, except adjuvant hormone&#xD;
             therapy started &gt; than or = to 12 months prior to study enrollment. Bisphosphonates&#xD;
             for management of bone metastases or osteoporosis/osteopenia are allowed&#xD;
&#xD;
         15. History of hypersensitivity to docetaxel (or drugs formulated in polysorbate 80),&#xD;
             epirubicin or doxorubicin&#xD;
&#xD;
         16. Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
         17. Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique AGNETTI</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>May 29, 2009</last_update_submitted>
  <last_update_submitted_qc>May 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

